Chronic Rhinosinusitis with Nasal Polyps
Conditions
Brief summary
Change from Baseline at Week 24 in NPS
Detailed description
Change from Baseline at Week 24 in the NCS evaluated by the NPSD, Change from Baseline at Week 24 in opacification of sinuses measured by LMK, Change from Baseline at Week 24 in DSS evaluated by the NPSD, Proportion of participants requiring systemic corticosteroids or NP surgery, Time to nasal polyposis surgery and/or time to systemic corticosteroids for nasal polyposis up to Week 24, Change from Baseline at Week 24 in NPSD TSS, AEs, SAEs, physical examinations, clinical laboratory assessments, vital signs, and ECGs from Baseline over study duration, including the Follow-Up Period
Interventions
Sponsors
Upstream Bio Inc.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline at Week 24 in NPS | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline at Week 24 in the NCS evaluated by the NPSD, Change from Baseline at Week 24 in opacification of sinuses measured by LMK, Change from Baseline at Week 24 in DSS evaluated by the NPSD, Proportion of participants requiring systemic corticosteroids or NP surgery, Time to nasal polyposis surgery and/or time to systemic corticosteroids for nasal polyposis up to Week 24, Change from Baseline at Week 24 in NPSD TSS, AEs, SAEs, physical examinations, clinical laboratory assessments, vital signs, and ECGs from Baseline over study duration, including the Follow-Up Period | — |
Countries
Czechia, Germany, Poland, Spain
Outcome results
None listed